Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Evotec SE
  6. News
  7. Summary
    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report
Delayed Xetra  -  11:35:18 2023-01-27 am EST
18.81 EUR   -0.56%
01/26Sector Update: Healthcare Stocks Climb Back to Finish Higher
MT
01/26Sector Update: Health Care Stocks Advance Pre-Bell Thursday
MT
01/26Evotec, Johnson & Johnson's Janssen Biotech Enter Cancer Drug Development Collaboration
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

EVOTEC : Receives a Buy rating from RBC

11/28/2022 | 02:32am EST

Already positive, the research from RBC and its analyst Zoe Karamanoli still consider the stock as a Buy opportunity. The target price has been revised downwards and is now set at EUR 28 as compared to EUR 35 previously.


ę MarketScreener with dpa-AFX Analyser 2022
All news about EVOTEC SE
01/26Sector Update: Healthcare Stocks Climb Back to Finish Higher
MT
01/26Sector Update: Health Care Stocks Advance Pre-Bell Thursday
MT
01/26Evotec, Johnson & Johnson's Janssen Biotech Enter Cancer Drug Development Collaboration
MT
01/26Evotec Shares Climb After Agreement With Janssen on Immunotherapies Development
DJ
01/26Evotec Starts Oncology-development Collaboration With Johnson & Johnson Unit
MT
01/26Evotec SE Announces Agreement with Janssen to Develop Immune-Based Therapies
CI
01/26Evotec : announces agreement with Janssen to develop immune-based therapies
PU
01/26Evotec announces agreement with Janssen to develop immune-based therapies
EQ
01/24EVOTEC : Receives a Buy rating from Warburg Research
MD
01/20Dd : Evotec SE: Dr. Craig Johnstone, Purchase of shares by exercising stock options (Shar..
EQ
More news
Analyst Recommendations on EVOTEC SE
More recommendations
Financials
Sales 2022 722 M 784 M 784 M
Net income 2022 -131 M -142 M -142 M
Net cash 2022 20,4 M 22,1 M 22,1 M
P/E ratio 2022 -24,6x
Yield 2022 -
Capitalization 3 324 M 3 608 M 3 608 M
EV / Sales 2022 4,57x
EV / Sales 2023 4,06x
Nbr of Employees 4 715
Free-Float 90,0%
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 18,81 €
Average target price 26,93 €
Spread / Average Target 43,2%
EPS Revisions
Managers and Directors
Werner Lanthaler Chief Executive Officer
Enno Spillner Chief Financial Officer
Iris L÷w-Friedrich Chairman-Supervisory Board
Cord E. Dohrmann Chief Scientific Officer
Craig L. Johnstone Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
EVOTEC SE23.26%3 608
MODERNA, INC.7.58%72 745
LONZA GROUP AG17.24%42 787
IQVIA HOLDINGS INC.12.00%42 622
ALNYLAM PHARMACEUTICALS, INC.-2.55%28 465
SEAGEN INC.9.46%26 117